Written by JobSiteCare

September 8, 2020


The biggest news this week is that both Dr. Stephen Hahn, Commissioner of the Food and Drug Administration, and Dr. Tony Fauci of the NIH both said that a limited Emergency Use Authorization for at least one of the vaccines, and likely two of them, could be issued as early as late next month or early in November. The idea is that if the vaccine is looking to be effective, healthcare workers on the front lines of care would be immunized as part of an effort to ensure we have maximal care capacity in case of a new wave in the fall as cooler weather drives people indoors.

This also opened the first salvo in what will surely be an active political debate in determining who should get early priority on vaccines. Beyond healthcare workers and national security personnel, the National Academies of Science, Engineering, and Medicine issued a recommendation at the request of CDC. It places highly vulnerable populations, including nursing home residents, the homeless, Native Americans, and those incarcerated at the top of the list.

A small speed bump in the vaccine distribution effort was publicly identified this week. Initial projections show that some of the candidate vaccines will need to be stored at -94 degrees F (about the temperature of dry ice) and the remainder at a little below 0 F. The latter is manageable with typical medical freezers, but the former requires specialized laboratory-grade deep freezers. This will mean that typical distribution channels for vaccines through community clinics and pharmacies will not be viable and large scale vaccination centers, likely operated by public health agencies in conjunction with the National Guard will be required for ensuring maximal protection of available vaccine supplies.

The vaccine prioritization plan, with the difficulty in distribution, combined with the underlying distrust in government and authority could set the stage for a rocky winter, especially given the media’s penchant for maximization of any perceived inequities in services.

On the other hand, as people are seeing the changes in the epidemic with continually decreasing death and hospitalization rates, many may shrug off vaccination program bottlenecks and allow things to settle out over time.

In any event, as you are listening to news reports on vaccine effectiveness, keep in mind that there are really three measures of effectiveness and that reports are not focused on the most important because that is the more difficult to measure. The three measures are:

  • Effectiveness in preventing infection
  • Effectiveness in preventing illness
  • Effectiveness in preventing serious illness or death

Clearly, this third category is the most important since if we can prevent serious illness or death, the rest does not really matter that much. What is being measured, is the effectiveness in preventing infection because the incidence of death is not high enough to measurably study in the initial trials. Even with questions about the rate of infection prevention, if there are indications that the vaccine can prevent serious illness or death, then this will be a win. Keep that in mind when you hear initial effectiveness data being released. Remember that some years, flu vaccines have raw effectiveness rates below 50% (meaning 50 out of 100 people exposed to infectious doses of flu will get it even if immunized), but this is still felt to have significant importance for saving lives.


Pooled analyses of recent trends across multiple countries, including the US, were released this week. What this showed was that from a public health standpoint, the Infection Fatality Rates by age group were as follows:

  • Age less than 50 IFR was negligible
  • Age 50-64, IFR varied from 0.05% to 0.5% depending on comorbidities
  • Age 65 to under 75, IFR was 5% to 10% depending on comorbidities
  • And over 75, IFR was consistently over 10%

It’s very important to understand these relative risks. As a point of comparison, a twenty-one-year-old has about a .04% annual fatality rate due to car accidents. It’s not hard to understand why a health college student is no more concerned about going to college parties where they might contract COVID-19 with a 0.05% fatality risk than they are about driving cars with a 0.04% annual fatality risk. Of course, that does not address the second-order effects, but college-age people are not traditionally good about considering these types of effects.


The virus is becoming LESS diverse as it continues to spread in the world. The concern has been that the virus could modify and become more virulent, but this is not happening at all. This is great news for the vaccine.

  • Over 80% of elderly nursing home residents in the UK who have recovered from the virus developed a measurable protective antibody response. That does not mean that 20% are not immune as other components of the immune system will also contribute to resistance. This also is great news for vaccines for this age group.
  • A very large study in Iceland has shown that over 90% of the population known to have been infected with SARS CoV2, including one-third of whom were asymptomatic, developed an adequate antibody response and after 4 months the antibody levels have not declined.
  • Many news outlets have published breaking news over the last two days about the use of common steroids in hospitalized patients in decreasing death rates by as much as one-third. Followers of these blogs know this is old news, it’s just that the World Health Organization is getting around to agreeing with the data.
  • Lastly, for anyone who is very skeptical of the new technology vaccines that will be the first to emerge from the Warp Speed project, a very conventional vaccine from Novovax Corporation of Maryland recently reported that 100% of subjects in its phase 1 and 2 studies developed an adequate antibody response. Phase 3 trials begin next month, and they believe they will be able to produce 100M doses by 1stquarter next year and a billion doses during 2021.